Cover Image
Market Research Report

Injectable Drug Delivery Devices Market - Growth, Trends, and Forecasts (2020 - 2025)

Published by Mordor Intelligence LLP Product code 871451
Published Content info 114 Pages
Delivery time: 2-3 business days
Back to Top
Injectable Drug Delivery Devices Market - Growth, Trends, and Forecasts (2020 - 2025)
Published: August 1, 2020 Content info: 114 Pages

The injectable drug delivery devices market is expected to show rapid growth due to the growing burden of chronic diseases, benefits, and convenience, leading to increased demand for self injectors and growth of the biologics market, leading to increased demand for injectors.

The growing burden of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes. It has been observed that most deaths by chronic diseases can be attributed to cardiovascular diseases, obesity, and diabetes. This is expected to affect the emerging countries the most, as population growth is found to be the most significant factor in developing areas.

A major number of drugs and therapies that address these chronic ailments are now found to be available. However, the use of syringes in the management of any chronic ailment is inevitable. Syringes can either be a part of sample collection during diagnosis or treatment regimen, like osteoarthritis. Consequently, the rise in the prevalence of chronic diseases is expected the drive the growth of the market studied.

Furthermore, technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market are some of the other factors propelling the growth of the market.

Key Market Trends

Self-injectable Drug Delivery Devices is Anticipated to be Dominant during the Forecast Period

There have been boundless innovations and developments in self-injectable devices which is driving the growth of the market. The other major advantages associated with self-injectable devices are that they are found to be of convenient usage and low healthcare cost. These self-injectables were developed with the help of patient feedback, to provide the most adaptable devices, which have high precision of drug delivery, and are easy to use.

In addition to this, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. Nevertheless, the advantages of self-injectable injections and increasing awareness of self-administration have helped in driving the overall market studied, during the forecast period.

The North America Region Dominates the Injectable Drug Delivery Devices Market

North America has been found dominating the injectable drug delivery devices, due to the increasing aging population and the rising number of chronic diseases that may influence the usage of injectables. According to the National Cancer Institute, 2018, there were an estimated 1,735,350 new cases of cancer that were being diagnosed in the United States. Therefore, chemotherapy drugs are being delivered to these cancer patients through injectable devices. Hence, increasing prevalence of chronic diseases and the adoption of new technologies related to injectables in the United States may help in propelling the growth of the overall market.

There are also some of the other factors that include; the large pool of patient population, increasing healthcare expenditure, rising focus of various companies, increasing healthcare awareness, and increase in government funding. Hence, all these factors are found associated with the growth of the market.

Competitive Landscape

The companies present in the market are found focusing on product innovations, expansions, finding new markets, or innovating their core competency to expand their individual market shares. There are also innovations taking place in injectable drug delivery systems that are the trend for the global injectable drug delivery market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Table of Contents
Product Code: 52626



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Chronic Diseases
    • 4.2.2 Benefits and Convenience in Self Injectors
    • 4.2.3 Growth of the Biologics Market Leading to Increased Demand for Injectors
  • 4.3 Market Restraints
    • 4.3.1 Injuries and Infections Caused by Needles
    • 4.3.2 Increasing Use of Alternative Delivery Methods
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Devices Type
    • 5.1.1 Conventional Drug Delivery Devices
    • 5.1.2 Advanced Drug Delivery Devices
      • Prefilled Syringes
      • Injectable Pens
      • Auto Injectors
      • Needle-free Injectors
      • Other Device Types
  • 5.2 By Therapeutic Application
    • 5.2.1 Cardiovascular Disease
    • 5.2.2 Diabetes
    • 5.2.3 Oncology
    • 5.2.4 Autoimmune Disorders
    • 5.2.5 Hepatitis
    • 5.2.6 Other Therapeutic Applications
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East & Africa
      • GCC
      • South Africa
      • Rest of Middle-East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Baxter International Inc.
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Gerresheimer AG
    • 6.1.5 Novo Nordisk A/S
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Schott AG
    • 6.1.8 Terumo Corporation
    • 6.1.9 Teva Pharmaceutical Industries Ltd
    • 6.1.10 West Pharmaceutical Services Inc.


Back to Top